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Abstract
MicroRNAs play an important role in the regulation of mRNA translation and have therapeutic potential in cancer and other
diseases. To profile the landscape of microRNAs with significant cytotoxicity in the context of glioblastoma (GBM), we
performed a high-throughput screen in adult and pediatric GBM cells using a synthetic oligonucleotide library representing all
known human microRNAs. Bioinformatics analysis was used to refine this list and the top seven microRNAs were validated in a
larger panel of GBM cells using state-of-the-art in vitro assays. The cytotoxic effect of our most relevant candidate was assessed
in a preclinical model. Our screen identified ~100 significantly cytotoxic microRNAs with 70% concordance between cell lines.
MicroRNA-1300 (miR-1300) was the most potent and robust candidate. We observed a striking binucleated phenotype in miR-
1300 transfected cells due to cytokinesis failure followed by apoptosis. This was also observed in two stem-like patient-derived
cultures. We identified the physiological role of miR-1300 as a regulator of endomitosis in megakaryocyte differentiation where
blockade of cytokinesis is an essential step. In GBM cells, where miR-1300 is normally not expressed, the oncogene Epithelial
Cell Transforming 2 (ECT2) was validated as a direct key target. ECT2 siRNA phenocopied the effects of miR-1300, and ECT2
overexpression led to rescue of miR-1300 induced binucleation. We showed that ectopic expression of miR-1300 led to
decreased tumor growth in an orthotopic GBM model. Our screen provides a resource for the neuro-oncology community and
identified miR-1300 as a novel regulator of endomitosis with translatable potential for therapeutic application.
Introduction
MicroRNAs are small 22–24 nt single-stranded noncoding
RNAs that function by reducing the translation of target
mRNAs. In glioblastoma (GBM), they have been shown to
play roles in proliferation, invasion, and stemness, sug-
gesting that microRNAs and their downstream pathways
may represent potent therapeutic targets [1–6]. There are an
increasing number of microRNA mimics and inhibitors in
preclinical and early clinical development as cancer thera-
pies, including one for patients with solid tumors using an
oligonucleotide mimic of microRNA-34 (MRX34,
NCT01829971) [7–10]. Recent preclinical studies showed
efficacy of a microRNA expressing therapeutic vector in
GBM [11]. MicroRNA-10b expression has been measured
in a clinical trial (NCT01849952) to assess its use as a
prognostic and diagnostic biomarker. An inhibitor of miR-
10b is also currently at the preclinical development stage
(Regulus Therapeutics Inc. and [12]).
Current approaches for microRNA studies in GBM
mainly involve endogenous microRNA expression profiles
coupled with bioinformatic analysis and target identification
to link the landscape of microRNA expression to GBM
biology and disease outcome [13–15]. Other functional
studies have focused on small numbers of microRNAs and
very few large-scale functional studies have been performed
in GBM [16].
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To assess the landscape of potential cytotoxic micro-
RNAs in GBM we decided on a global approach by per-
forming a large-scale functional screen. We used a
microRNA mimic oligonucleotide library combined with a
high-throughput imaging platform to identify microRNAs
that significantly impaired proliferation and/or survival of
GBM cells. This approach highlighted microRNA-1300 as
a candidate for more detailed characterization. We found
that miR-1300 is not typically expressed in GBM, and that
ectopic expression of its mature form following transfection
consistently caused a G2/M cell cycle arrest followed by
apoptosis. Further validation showed that forced expression
of miR-1300 in GBM cells caused cytokinesis failure and
that the oncogene Epithelial Cell Transforming 2 (ECT2) is
one of the direct targets of miR-1300 involved in this
phenotype. This, in turn, led us to identify the key phy-
siological need for the finely tuned, cell, and stage-specific,
expression of miR-1300 during endomitosis in platelet
formation from megakaryocytes [17–19]. Finally, we con-
firmed the cytotoxicity of ectopic expression of miR-1300
in a preclinical orthotopic model of GBM. Taken together,
our study not only provides an encompassing profile of
cytotoxic microRNAs toward adult and pediatric GBM cells
but also identifies miR-1300 as a uniquely specific tool with
a potential therapeutic window for combination with current
standard therapy in GBM. Our dataset will provide a useful
resource for researchers in the field with an interest in the
therapeutic application of microRNAs.
Results
A high-throughput screen identifies microRNAs with
cytotoxic activity in GBM
We profiled cytotoxic microRNAs in adult and pediatric
GBM cells using a high-throughput high-content screen
based on a library that encompassed mimics of the mature
form of all annotated microRNAs based on miRBase v16.0
at the time. The screen was performed in two established
GBM cell lines: U251 (adult GBM) and KNS42 (pediatric
GBM). A schematic of the screen is shown in Supple-
mentary Fig. 1. The chosen primary end-point read out was
a decrease in cell number assessed by automated nuclei
counting at 72 h post transfection.
The candidate hit list for KNS42 and U251 cells con-
tained 83 and 304 hits, respectively (see Supplementary
Tables 1 and 2 for the complete screen datasets). The U251
list was re-analyzed using a <−3 standard deviation cutoff
(see “Methods” for details), which gave 111 hits to consider
for further analysis. Based on the Z-score analysis, we
initially observed a 70% overlap between the candidate lists
for each cell line (Supplementary Table 3) and focused
further investigations on those microRNAs. We utilized the
online microRNA databases miRBase [20–24] and Tar-
getscan [25–31], as well as PubMed (National Center for
Biotechnology Information, National Library of Medicine,
Bethesda, MD, USA) to gather available information for
each of the “hit” microRNAs: chromosomal location, main
validated and predicted target genes, associated functions
and role in disease. This approach shortlisted 18 candidate
microRNAs. The second level of analysis took into con-
sideration the strength of the Z-score, together with infor-
mation focused on seed sequence family and the association
of the target genes with cell proliferation and/or cell death
and led to the selection of seven microRNAs for validation
in cell-based assays. The endogenous levels of expression
of those seven microRNAs were verified in our established
cell line models and found mostly not expressed in our cells
(Supplementary Fig. 2). We applied the conditions of the
primary screen to four established GBM cell lines (U251,
KNS42, LN229, and U373), confirming statistically sig-
nificant cytotoxicity following transfection of all seven
mimic-microRNAs (Supplementary Fig. 3a).
In order to investigate whether cytotoxicity was due to
programmed cell death, we measured the number of cleaved
caspase-3 foci by immunofluorescence. Interestingly, only
transfection with the mimic for miR-1300 led to the clea-
vage of caspase-3 and apoptotic cell death (Supplementary
Fig. 3b, c).
We then focused further on characterizing the role and
mechanism of action of miR-1300; based on its high Z-
scores (Z-score=−2.98 in KNS42 and Z-score=−5.14 in
U251), and its ability to induce apoptosis. MiR-1300 mature
and precursor sequences as well as alignment to the human
genome are described in Supplementary Table 4.
MiR-1300 induces cytokinesis failure, cell cycle
arrest and apoptosis in GBM cell lines and
patient-derived GBM
Flow cytometry-based assays were used to measure the
effect of ectopic expression of miR-1300 in its mature form
(MIMIC) on cell cycle and cell death over time. Expression
of miR-1300 induced a cell cycle significant block in G2/M
at 24 h in U251 and 48 h in KNS42 cells (Fig. 1a) with a
multinucleation phenotype (Fig. 1b), rapidly followed by
the onset of apoptosis (Fig. 1c). In miR-1300 treated
U251 cells there was a > 60% reduction in cells in G0/G1
with a 1.5-fold increase in G2/M cells at 24 h compared
with the scrambled control (p= 0.0079**, Fig. 1a). This
G2/M arrest became more pronounced at 48 h (~2.5-fold
change, p < 0.0335*) and 72 h (threefold change, p <
0.0485*) but was no longer apparent at 96 h following high
levels of apoptosis (Fig. 1c) with >20% reduction in the
number of live cells and approximately three- and sixfold
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increase of cells in early-mid and mid-late apoptosis (p=
0.0012** and p < 0.0001****, respectively, Fig. 1b).
Similar changes in the cell cycle profile were observed in
KNS42 cells with an approximately four- and approxi-
mately threefold increase in cells in G2/M at 48 and 72 h (p
= 0.017* and p= 0.009**), respectively. Analysis of
immunofluorescently stained cells from the screen showed
that cell cycle arrest observed by flow cytometry occurred
during mitosis, where 72 h post transfection, ectopic
expression of miR-1300 caused ~80% and >60% increase in
binucleated cells in U251 and KNS42, respectively (p <
0.0001****; Fig. 1c). The same phenotype was observed in
LN229 and U373 GBM cell lines (Supplementary Fig. 4).
The binucleation we observed (Fig. 1c) suggested that cell
cycle arrest took place after telophase and was representa-
tive of cytokinesis failure. Live cell imaging confirmed that
both KNS42 (Supplementary Movie 1A) and U251 cells
(Supplementary Movie 1B) transfected with miR-1300
initiated mitosis normally but failed to complete the final
stages of cytokinesis, resulting in the formation of multi-
nucleated cells.
Next, we sought to confirm that this phenotype was also
observed in patient-derived glioma stem-like cells (GSCs)
as a more representative in vitro model. In two previously
characterized GSCs, GBM1 and GBM4 [32, 33] new time
courses for the flow cytometry assays were performed at 72,
96, and 120 h to reflect the slower division rate of the
patient-derived cells. Similarly, imaging experiments were
replicated with binucleation scoring at 96 h. Transfection of
GBM1 with mimic-miR-1300 caused a profound G2/M
phase block with a fourfold increase in the proportion of
cells in G2/M phase at 72, 96, and 120 h compared with
cells transfected with the scrambled-mimic control (Fig. 2a).
Transfection with mimic-miR-1300 also caused a twofold
reduction in the number of cells in G0/G1 and S-phase
(Fig. 2a). This G2/M arrest led to an overall reduction in
live cells of ~40%, 45%, and 80% at 72, 96, and 120 h and a
significant increase (p < 0.01 and p < 0.05 in GBM1 and
GBM4, respectively) in apoptotic cells at 120 h (Fig. 2b).
Similar results were observed in GBM4 GSCs with miR-
1300 causing a 65% reduction in cells in S-phase at 72 h,
which was maintained at 96 h. At 96 h there was an increase
Fig. 1 Effect of miR-1300 expression on proliferation and cell
death in U251 and KNS42 cell lines. a Cell cycle time course ana-
lyzed by flow cytometry using propidium iodide (PI) loading as a
measure of DNA content. b Binucleation phenotype scoring following
following 72 h of treatment and staining with DAPI and Phalloidin
Alexafluor488 (Actin) and the corresponding representative image. All
experiments were performed in triplicate. The results are normalized to
a scrambled-mimic control. c Cell death measured by flow cytometry
where Annexin negative (An−)/PI negative (PI−)= live cells, An+=
early-mid apoptotic cells, An+ PI+=mid-late apoptotic cells and An
− PI+= necrotic cells. Statistical significance is expressed as follows:
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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in cells on G2/M phase by fourfold for GBM1 and by
twofold for GBM4 (Fig. 2a). At 96 h, miR-1300 transfection
resulted in a ~40% reduction in live cells and an increase of
around 20% in early-mid apoptotic GBM1 cells. By 120 h
there was a ~75% decrease in live cells and a 1.5-fold
increase in early-mid apoptotic cells for both GBM1 and
GBM4, and 2.5 and 1.5-fold increase in mid-late apoptotic
cells for GBM1 and GBM4, respectively (Fig. 2b). Figure
2c, d shows the effect of miR-1300 on the number of bi- and
multinucleated cells. As with the established cell lines, miR-
Fig. 2 Effect of miR-1300 expression on proliferation and cell
death in GSC cultures GBM1 and GBM4. a Cell cycle time course
analyzed by flow cytometry using propidium iodide (PI) loading as a
measure of DNA content. b Cell death measured by flow cytometry
where Annexin negative (An−), PI negative (PI−)= live cells, An+
PI−= early-mid apoptotic cells, An+ PI+=mid-late apoptotic cells
and An− PI+= necrotic cells. c, d Binucleation phenotype scoring
following staining with DAPI and Phalloidin Alexafluor488 (Actin)
(3–6 images per condition, representing at least 100 cells) was per-
formed on images taken on the Operetta imaging platform (×10
objective). All experiments were performed in triplicate. The results
are normalized to a scrambled-mimic control. Statistical significance is
expressed as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ****p <
0.0001.
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1300 caused a decrease in mono-nucleated cells of ~90% in
both GBM1 and GBM4 and a significant increase (~50%) in
binucleated cells for both GSCs (Fig. 2c, d), (p= 0.0055**
and p= 0.0081**, respectively).
Taken together, this initial characterization showed that
ectopic expression of miR-1300 consistently led to cyto-
kinesis failure, measured by cell cycle arrest in G2/M phase
and manifested by a striking binucleated phenotype fol-
lowed by the onset of apoptosis as documented by caspase-
3 cleavage (Supplementary Fig. 3b, c) and expression of
Annexin V/PI (Figs. 1b and 2b). This was confirmed both in
established GBM cells and in patient-derived GSCs.
Identification of miR-1300 target genes
Since there are no validated target genes for miR-1300, we
used the list of predicted targets extracted from the online
database TargetScan v5.2 [29]. This contains 3327 target
genes predicted to be targeted by miR-1300 irrespective of
the presence of conserved sites (the seed sequence for miR-
1300 is poorly conserved across species). This list was
analyzed using Metacore gene software (Thomson–Reuters)
and cross-referenced using AmiGO [34] for “cytokinesis”
as a Gene Ontology term. This identified which of the miR-
1300 target genes had the highest potential involvement in
the observed cytokinesis failure, resulting in a list of 21
potential target genes (Supplementary Table 5). Based on
the characteristic binucleation seen in our phenotype, the
Targetscan prediction score, and the literature, we chose to
focus on the guanine nucleotide exchange factor (GEF)
ECT2 gene as our target of interest for initial validation.
Interestingly, ECT2 has been previously described as an
oncogene and has been shown to contribute to the invasive
behavior of GBM cells [35–39]. Analysis of survival data in
gliomas in the Rembrandt (REpository for Molecular
BRAin Neoplasia DaTa) dataset showed that patients with
increased levels of ECT2 mRNA have a lower survival than
those with intermediate levels (Fig. 3). ECT2 plays a crucial
role in cytokinesis through activation of the small GTPase
RhoA, a key protein in the formation of the mitotic cleavage
furrow during cytokinesis [17, 18]. Also, treatment of cells
with RhoA inhibitors caused a binucleated phenotype
similar to that observed in the GBM cell lines following
transfection with miR-1300 [40]. Further, ECT2 depletion
has been shown to lead to cytokinesis failure by impairment
of cleavage furrow formation [41].
Using Real-Time qPCR in a panel of five patient-derived
GSCs, an inverse relation between ECT2 mRNA and miR-
1300 expression was observed (Supplementary Fig. 5a).
This is consistent with the frequency of multinuclear cells
observed during cell culture (Supplementary Fig. 5b).
Together, these data implicate ECT2 as a miR-1300 target
that may play a role in mediating its effects on GBM cells.
ECT2 is a direct target of miR-1300
To validate ECT2 as a direct target of miR-1300, U251 and
KNS42 cells were transfected with siRNAs directed against
ECT2 (~95% reduction in U251 and ~80% reduction in
KNS42 (Fig. 4a and Supplementary Fig. 6b)). ECT2
siRNA-mediated knockdown replicated the binucleated
phenotype induced by miR-1300 observed for mimic-miR-
1300 (Fig. 4b, c, left hand side). Transfection of U251 cells
with miR-1300 caused ~30% and 7% increase in bi- and
multinuclear cells, respectively. Consistent with identifica-
tion of ECT2 as a miR-1300 target, transfection with miR-
1300 induced a decrease in the expression of ECT2 of
~70% and 50% in U251 and KNS42 cells, respectively (Fig.
4d and Supplementary Fig. 6a); siRNA-mediated knock-
down of ECT2 caused an increase in bi- and multinucleated
cells of ~40% and 15%, respectively. A similar trend was
observed in KNS42 cells (Fig. 4b, c, right hand side).
Western blotting experiments confirmed that transfection
with miR-1300 induces a decrease in the expression of
ECT2 of ~70% and 50% in U251 and KNS42 cells,
respectively (Fig. 4d and Supplementary Fig. 6a). Experi-
ments in the patient-derived GSCs also showed that indi-
vidual ECT2 siRNAs led to a significant increase in
binucleated cells (Supplementary Fig. 7). Structural differ-
ences in actin and tubulin between miR-1300 expressing
and ECT2 knockdown cells were observed by immuno-
fluorescence (Fig. 4b). This suggests that other miR-1300
target genes, likely from the list of 21 targets we previously
identified (Supplementary Table 5), affect its downstream
phenotype.
Having shown that the miR-1300 phenotype is consistent
across a range of established and patient-derived GBM lines
and that ECT2 is a promising target of miR-1300, direct
targeting was confirmed using 3′UTR reporter assays. Cells
were transfected with a luciferase reporter containing either
the wild-type ECT2 3′UTR (3′ECT2) region or a mutated
version of the ECT2 3′UTR (3′ECT2-mt) harboring two
point mutations in the predicted miR-1300 seed region. Co-
transfection of either KNS42 or GBM4 with miR-1300 and
3′ECT2 caused a significant reduction in reporter signal
(Fig. 5a, b, respectively). In cells transfected with 3′ECT2-
mt the effect of miR-1300 on the reporter signal was
abolished thus showing that the ECT2 3′UTR is a direct
target of miR-1300 (Fig. 5a, b, respectively).
In order to further validate the involvement of ECT2 in
the pathway downstream of miR-1300, we performed res-
cue experiments as follows; 36 h following transfection
with miR-1300 in KNS42 cells (~60 h in GBM1 cells), cells
were transfected again with an expression vector for ECT2
(lacking the 3′UTR region) in an attempt to rescue cells
from cytokinesis failure. We showed that re-expression of
ECT2 caused a 50% reduction in the number of binucleated
Profiling cytotoxic microRNAs in pediatric and adult glioblastoma cells by high-content screening,. . .
cells in both KNS42 and GBM1 cells (Fig. 5c, d). Overall,
these data confirm that the effect of miR-1300 expression is
mediated via reduced ECT2 levels, which drive failed
cytokinesis and apoptosis in glioma cells.
MiR-1300 and ECT2 as regulators of endomitosis
Endogenous levels of ECT2 mRNA and protein are known
to be decreased during megakaryocytic differentiation at the
endomitotic stage when multinucleation occurs [19]. This
suggests a likely regulatory role for miR-1300 on ECT2
expression levels in platelet formation which is supported
by low levels of miR-1300 remaining in platelets post
terminal differentiation (see Supplementary data of Ref.
[15]) [19, 42]. Using the megakaryocytic cell (MKC) line
CMK [43] and the Src inhibitor SU6656 which induces
endomitosis and differentiation of CMK cells into platelets
[43, 44], these phenotypes were confirmed and this model
of induced endomitosis utilized to validate this previously
undescribed physiological role of miR-1300. We measured
a time dependent increase in expression of endogenous
microRNA-1300 in CMK cells by approximately fourfold
Fig. 3 The Rembrandt
database was used to search
for a correlation between the
levels of ECT2 mRNA and
survival in glioma patients. We
found a significant difference in
survival between glioma patients
with higher levels of ECT2
mRNA and patients with
intermediate ECT2 mRNA
levels. This was also true when
compared to all glioma samples
in the database.
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at 48 h, and approximately sixfold at 72 h and a concomitant
decrease in ECT2 protein levels following exposure to 5 μM
SU6656 (Fig. 6a and Supplementary Fig. 8). Moreover, we
confirmed the increase of polyploid MKC by nearly twofold
at 24 h, and 1.5-fold both at 48 h and 72 h, respectively,
using high-content immunofluorescence imaging (Fig. 6b).
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Differentiated brain tumor cells are not affected by
miR-1300 expression
In order to establish whether the phenotype caused by miR-
1300 was specific to proliferating GBM cells, we assessed
the effect of its ectopic expression on fully differentiated
GSCs, compared with their stem-like, proliferative (iso-
genic) counterparts. Differentiation of GBM1 and GBM4
cells was achieved by 5 days exposure to BMP4 as pre-
viously described [32, 33, 45–47]. First, we confirmed that
BMP4 exposure significantly decreases proliferation in
miR-1300 transfected cells (Supplementary Fig. 9).
In GBM1 cells, transfection with miR-1300 caused a
fourfold increase in the proportion of cells in G2/M phase,
which was significantly reduced by 2.3-fold in the BMP4
differentiated counterparts (Fig. 7a). MiR-1300 caused a
1.5-fold reduction in live cell numbers, a 3.8-fold increase
in early apoptotic cells and a 14-fold increase in apoptotic
cells, whereas there was no significant change in their dif-
ferentiated counterparts (Fig. 7b). A reduction by half in the
number of binucleated cells in BMP4 differentiated GSCs
compared with nondifferentiated cells was observed.
GBM4 cells showed a 0.8-fold increase in cells in G2/M
after transfection with miR-1300, which was reduced to a
0.2-fold after BMP4 treatment (Fig. 7a). MiR-1300 caused a
50% reduction in live GBM4 cells and a 3.8- and fourfold
increase in early-mid apoptotic and mid-late apoptotic cells,
respectively. However, cell death was significantly reduced
in BMP4 treated postmitotic GBM4 cells transfected with
miR-1300, to the point where there were no significant
differences in comparison with the scrambled control
transfected cells (Fig. 7b). BMP4 treated GBM4 cells did
not show an increased number of binucleated cells com-
pared with control cells, as opposed to their non-
differentiated counterparts (Fig. 7c). Taken together these
data suggest that expression of miR-1300 in nonproliferat-
ing, differentiated cells does not induce significant cell cycle
arrest or apoptosis when compared with proliferating,
undifferentiated (stem-like) isogenic pairs. This suggests
that miR-1300 could represent an attractive target with a
favorable therapeutic rational in GBM.
Ectopic expression of miR-1300 decreases tumor
growth in an orthotopic GBM mouse model
To assess the effect of miR-1300 in a preclinical mouse
GBM model we reverse-transfected U87 cells with miR-
1300 or a negative control microRNA (Scrambled), as
before. Cells remained in culture for 2½ days to maintain
balance between transfection efficiency and cell death due
to the miR-1300 phenotype. Three animals per group
received an intracranial implantation of transfected U87
cells. Tumor volume was measured by MRI at day 26 upon
the first sign of neurological symptoms, showing a decrease
in tumor volume in the miR-1300 group in comparison to
controls (Fig. 8). Of note, the MRI images in Fig. 8c shows
that the larger tumor in the miR-1300 group (top right
image) displays some structural differences compared with
the control tumors of equivalent volumes. The contrast in
this tumor is less than that of the control tumors and it edges
of the tumor are also more diffuse. Thus, miR-1300 trans-
fection results in a demonstrable alteration in tumor growth
in vivo and will be explored in further studies.
Discussion
GBM is an aggressive brain tumor with no effective treat-
ment [48]. MicroRNAs are well-known as important reg-
ulators of cellular functions [3–5] and several have been
shown to have therapeutic potential, either by over-
expression or inhibition by antisense oligonucleotides.
Thousands of microRNAs are encoded in the human gen-
ome, therefore, to investigate which microRNAs may have
effects on GBM growth and to identify novel sensitivities
and potential therapeutic approaches we performed a high-
throughput screen of a microRNA library comprising all
known human microRNAs (miRBase v16). Our high-
throughput high-content screen defined the landscape of
microRNAs with significant cytotoxic effects in adult and
pediatric GBM cell lines. We identified over 100 micro-
RNAs with significantly potent effects in our screen, which
are fully disclosed in this paper. The results of this study
should therefore provide a major resource for the GBM
field, as many of these microRNAs are yet unstudied in
GBM or other contexts. We validated our top hits in an
extended panel of GBM-derived cells and based on overall
potency and induction of apoptotic cell death we followed
Fig. 4 Reduced ECT2 levels in response to miR-1300 expression is
associated with cytokinesis failure in U251 and KNS42 cell lines.
a Confirmation of ECT2 knockdown at the protein level (by WB)
following transfection with ECT2 siRNA smartpool. All experiments
were performed in triplicate. The results were normalized to a
scrambled-mimic control. b Transfection with ECT2 siRNA leads to
an increase in binucleated cells. Binucleation phenotype scoring (3–6
fields of view (FOV) per condition, representing at least 100 cells) was
performed on images taken on the Operetta imaging platform (×10
objective). c Immunofluorescence images comparing the actin and
alpha-tubulin staining in U251 and KNS42 cells 72 h following
transfection with 100 nM of either miR-1300 or ECT2 siRNA showing
both the common effect on binucleation (DAPI, blue) and the com-
parative differences in actin (Phalloidin) and a-tubulin structures
(Alexafluor488, green). Scale bar= 100 mm. d Ectopic expression of
miR-1300 leads to decreased expression of ECT2 at the protein level.
Statistical significance is expressed as follows: **p < 0.01; ****p <
0.0001. NB: Blot images were taken at 48 h time point since at 72 h,
cells in control conditions have reached confluence, and were no
longer expressing ECT2 as they are not dividing.
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up in detail the effects of miR-1300. Ectopic expression of
miR-1300 after transfection of oligonucleotide mimics leads
to a distinctive phenotype of cytokinesis failure followed by
apoptosis in both established GBM cell lines and in patient-
derived GBM cultures. Prior to their death, cells acquire a
distinctive bi-/multinucleated phenotype due to cytokinesis
failure. We used bioinformatics analysis followed by
functional analyses to identify and validate ECT2 as a direct
target and critical effector downstream of miR-1300. Ect2 is
a Rho-GEF with known functions in cell division [40–44].
MicroRNAs are frequently altered in cancer and repre-
sent bona fide clinical agents particularly when applied in
combination with effective viral or nanoparticle delivery
systems. Clinical trials are underway in liver cancer and
multiple microRNA-based strategies are in development for
the treatment of cancer [8]. Our next series of experiments
will employ viral vectors to deliver miR-1300 in vivo. Here,
we focused on detailed studies of in vitro cell killing and
cellular phenotypes, showing a remarkably robust defect in
cytokinesis. Our pilot in vivo data shows that miR-1300
effects are reflected in tumor growth in an orthotopic GBM
model, supporting further therapeutic studies.
MiR-1300 has not previously been studied in terms of its
biological function. Our investigations led us to find that
miR-1300 has an important physiological function in
megakaryocyte differentiation, in which platelets are
formed by punching-off from a multinucleated mega-
karyocyte parental cell in the bone marrow [19]. This fas-
cinating observation relates to its function in GBM cell
killing and reveals that microRNAs with nontumor related
physiological functions may be applicable in the treatment
of disease, particularly cancer.
Fig. 5 ECT2 is a direct target
of miR-1300. Direct targeting
assessed by 3′UTR luciferase
assay in the KNS42 cells (a) and
GBM4 GSCs (b). 3′ECT2
represents the wild-type 3′UTR
sequence, 3′ECT2-mt represents
the 3′UTR sequence containing
two point mutations in the
predicted binding site for the
miR-1300 seed sequence.
Ectopic expression of ECT2
rescues miR-1300 induced
cytokinesis failure. Binucleation
phenotype scoring (3–6 FOV
per condition, representing at
least 100 cells) was performed
on images taken on the Operetta
imaging platform (×10
objective) in KNS42 (c) and
GBM1 (d). All experiments
were performed in triplicate. The
results are normalized to the
double control: “MIM control+
Control vector” representing the
scrambled-mimic combined with
the empty vector devoid of the
ECT2 expression cassette.
Statistical significance is
expressed as follows: **p < 0.01
and ****p < 0.0001.
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The susceptibility of GBM to cell cycle blockade should
be further explored. We are currently investigating whether
miR-1300 alone or in combination with other microRNAs or
siRNAs expressed as an artificial miR Cluster as described by
Bhaskaran et al. [11] will be a more effective inducer of cell
cycle blockade and cell death. Indeed, intratumoral delivery
of these multiple microRNA expressing constructs can be
much more effective than expressing a single microRNA and
offer a further advantage of exosomal intercellular spread
throughout the tumor microenvironment.
The effect of miR-1300 shows its translational potential as
a treatment for GBM. It also may be a very promising can-
didate for combination therapy as a chemo-radiosensitizer
decreasing the ability of dividing cells to recover from the
damage induced by conventional therapy. Moreover, this
effect could be of paramount use in the second line of treat-
ment whereby specifically targeting resistant repopulating
cells it could also significantly impair recurrence.
Bioinformatics revealed additional targets beyond ECT2
of miR-1300, which may impact and reinforce the pheno-
type we observed. Some of these are under further inves-
tigation. Thus, our ongoing work is aimed at validating the
mechanism of action of miR-1300 in more molecular detail
as well as addressing delivery of microRNAs for brain
tumor treatment and its potential use in combination with
conventional treatments.
Fig. 6 Exposure of
synchronized CMK cells to
SU6656 concomitantly induces
an increase in the levels of
miR-1300 and a decrease of its
target, ECT2. a Cells were
synchronized using Monastrol
25 mM for 24 h prior to
exposure to SU6656 5 mM.
b Increase in multinuclear
megakaryocytic cells (MKC) as
a result of endomitosis
undergone by megakaryoblastic
cells (MKB) was measured by
immunofluorescence in response
to SU6656. Cells were stained
with DAPI and TOTO-3. Nine
fields of view were analyzed
using an algorithm designed in
the Columbus software to
discriminate objects based on
their size (b). Statistical
significance is expressed as
follows: *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001.
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Materials and methods
Please see Supplementary information for: cell line details,
and additional methods.
High-throughput screen
The miRIDIAN microRNA MIMIC library based on miR-
Base v16.0 was purchased from Dharmacon (GE
Fig. 7 Ectopic expression of miR-1300 specifically affects GBM
stem-like cells but not their differentiated counterparts. a Effect on
the cell cycle was analyzed by flow cytometry 120 h post transfection
using Propidium Iodide (PI) loading as a measure of DNA content.
b Cell death measured also 120 h post transfection by flow cytometry
where Annexin negative (An−), PI negative (PI−)= live cells, An+
PI−= early apoptotic cells, An+ PI+=mid/late apoptotic cells and
An− PI+= necrotic cells. c Binucleation phenotype scoring (3–6
images per condition, representing at least 100 cells) was performed on
images taken on the Operetta imaging platform (×10). All experiments
were performed in triplicate. The results are normalized to a
scrambled-mimic control without BMP4 exposure. Statistical sig-
nificance is expressed as follows: *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001.
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Healthcare). All microRNA mimics and siRNAs were
resuspended at a stock concentration of 20 μM in 1× siRNA
Buffer prepared from a 5× stock (Cat# B-002000-UB-100,
Dharmacon GE Healthcare) in RNase free water (Cat# B-
003000-WB-100, Dharmacon GE Healthcare). The screen
controls for cell number were MIMIC negative control #1
tagged with Dy547 (Cat# CP-004500-01-20) to calculate
transfection efficiency as well as without Dy547 (Cat# CN-
001000-01-20), which were included in eight separate wells
and PLK-1 siRNA SMARTpool (Cat# M-003290-01-005),
which was both the transfection control and the positive
control for decreased cell number. Reverse transfection was
performed on U251 and KNS42 cells using RNAiMAX
lipofectamine (Invitrogen, Life Technologies, Cat# 13778-
075), OPTI-MEM® I Reduced Serum Medium (Cat# 31985,
Gibco™, Invitrogen corporation) and 100 nM of RNA
material (MIMIC or siRNA candidates and controls). For the
screen, each well of a 96-well ViewPlate (6005182, Perkin
Elmer), contained 20 μl of transfection mix including: 0.1 μl
of RNAiMAX (137789-075, Life Technologies) commercial
stock solution, 0.1 μl of 20 μM microRNA, and 19.8 μl of
OptiMEM® media (31985-047, Life Technologies); to which
80 μl of growth media, containing 6 × 103 cells/well (U251)
or 9 × 103 cells/well (KNS42), were added giving a final
Fig. 8 Ectopic expression of
miR-1300 impairs tumor
growth in an orthotopic GBM
mouse model. a Tumor volumes
plotted in GraphPadPrism 8.
b Tumor volumes analyzed
using VivoQuant software.
c Representative MRI images
for each animal in the study.
Images were acquired using a 7T
MRI System (AspectImaging,
Watford, UK), using a T2
weighed fast spin echo scan for
10 min.
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volume of 100 μl per well. Plates were placed at 37 °C, 5%
CO2 for 72 h prior to being fixed in 4% PFA and stained
with DAPI (Cat# D1306, Life Technologies) for nuclei
count, TOTO-3 (Cat# T-3604, Molecular Probes) and
Phalloidin-A488 (Cat# A12379, Life Technologies) for
delimitation of the cytoplasm and actin structure.
Each 96-well plate contained one microRNA mimic or
microRNA control per well. Plates were imaged on a
Perkin-Elmer Operetta High-Content Imaging System using
Harmony 3.1 software, three fluorescent channels, ten-
fields/well with a 20× objective. For each cell line, the
screen was performed in two separate passages of cells.
An algorithm for nuclei counting based on DAPI stain was
designed in Columbus 2.4 analysis software. For the analysis,
the mean cell number of eight mimic negative control wells
was evaluated per plate and used to calculate the Z-score (the
number of standard deviations above or below the mean cell
number) for each mimic microRNA utilized. Candidate
microRNAs were identified as those which significantly
decreased cell number due to reduced proliferation and/or cell
survival only if their mean Z-score was greater or equal to two
standard deviations below the mean Z-score of the negative
controls for both biological replicates.
Induction of endomitosis
Endomitosis was induced by culturing nonadherent CMK
cells for up to 72 h in the presence of 5 μM of the Src kinase
inhibitor SU6656 (Sigma Aldrich) [43, 44]. Six milliliters of
cell suspension were harvested every day for 3 consecutive
days. Two milliliters were used to prepare RNA (SU6656
experiments only), 2 ml to prepare protein lysates for ECT2
western blot, and 2 ml were used for imaging.
Forced differentiation of glioma stem cells
Glioma stem cells were differentiated in the presence of
100 ng/ml BMP4 [32, 33, 47] (Life Technologies) for
4–5 days prior to transfection with mimic miRNA-1300 or
scrambled control. Cells were maintained in BMP4 sup-
plemented media following transfection.
Preclinical model
U87 cells were transfected either with a nontargeting mimic-
scrambled or our mimic-miR-1300 at 100 nM as described in
the screen conditions. Cells were then harvested 63 h post
transfection in order to achieve the best balance between
induction of the miR-1300 phenotype and cell death as per our
in vitro data.
Animal handling procedures and experiments were per-
formed in accordance with the UK Animal Scientific Pro-
cedures Act 1986 and covered by UK Home Office licenses
(University of Leeds ethics committee project license:
PA67C4EBE4). All animals are housed in Tecniplast green
line caging in a pathogen free environment, given 3R’s
bedding made from sterile recycled sterile paper material
and fed a diet of compound rat mouse (Special Diets Ser-
vices Ltd) and reverse osmosis filtered water.
At day 0, 1 × 10e5 viable U87 cells were orthotopically
implanted by intracranial surgery into three Balb C Nude
mice per cohort (Scrambled and miR-1300). Intracranial
injection co-ordinates were 1 mm rostral to bregma, 1.5 mm
lateral (right), and 4 mm deep.
Animals were then weighed and checked daily. MRI
images were taken on the day of the first animal showing
neurological symptoms which is this experiment fell on day
26 post surgery. MRI data were acquired using a 7T MRI
System (AspectImaging, Watford, UK), using a T2 weighed
fast spin echo scan for 10 min. Images were analyzed using
VivoQuant software.
Sample size and statistical analysis
With the exception of the high-throughput screen, all assays
were performed as three biological replicates (cells from
different passage number), each containing three technical
replicates. In the case of immunofluorescent imaging ana-
lysis, a minimum of 100 cells per condition were scored.
The unequal variance Welch’s, unpaired t-test was chosen
to test how far apart the two populations tested were
regardless of the difference in their standard deviation (for
example: microRNA-1300 vs control).
Data availability
The raw data from the screen are supplied in the supple-
mentary information as individual Excel files.
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